Af­ter land­ing funds from Roy­al­ty, Cy­to­ki­net­ics an­nounces afi­camten PhII re­sults; Pol­ish CRO Selvi­ta re­struc­tures in search for new growth

Cal­i­for­nia-based Cy­to­ki­net­ics an­nounced that pos­i­tive re­sults from a Phase II tri­al of afi­camten showed pos­i­tive re­sults in pa­tients bat­tling hy­per­trophic car­diomy­opa­thy.

The third co­hort of the RED­WOOD-HCM tri­al showed sub­stan­tial re­duc­tions in the av­er­age left ven­tric­u­lar out­flow tract gra­di­ent in pa­tients whose back­ground in­clud­ed be­ing treat­ed with disopy­ra­mide and a be­ta-adren­er­gic block­er. Each pa­tient re­ceived up to three dos­es dai­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER